| http://www.w3.org/ns/prov#value | - The FDA and other regulatory agencies globally struggle with ambiguities that typify the review process for routine submissions to the extent that these submissions reflect the state of risk analysis, risk mitigation, and risk communication, derived from the most current revisions of the internationally harmonized risk standards and terms of reference.
|
